Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.
About Cencora Inc. (Symbol: COR)
Cencora Inc., formerly known as AmerisourceBergen, stands as a pivotal player in the global healthcare supply chain, specializing in pharmaceutical distribution and related services. Operating at the intersection of healthcare delivery and supply chain logistics, Cencora ensures the efficient and secure distribution of branded, generic, and specialty pharmaceuticals, as well as over-the-counter (OTC) healthcare products. Its services are integral to pharmacies, hospital networks, healthcare providers, and pharmaceutical manufacturers, making it a cornerstone of the healthcare ecosystem.
Core Business Operations
Cencora’s business model is built around three primary pillars:
- Pharmaceutical Distribution: Cencora sources and distributes a wide range of pharmaceutical products to retail pharmacies (chains and independents), mail-order pharmacies, and healthcare providers. Its streamlined operations enhance product accessibility, cost-efficiency, and supply chain reliability.
- Commercialization and Manufacturer Services: The company offers end-to-end solutions for pharmaceutical and medical device manufacturers, maximizing product success throughout the lifecycle. These services include market access strategies, regulatory support, and commercialization solutions.
- Specialty Logistics and Animal Health: Through its World Courier division, Cencora provides global specialty drug logistics, ensuring the secure and timely delivery of high-value, temperature-sensitive pharmaceuticals. Additionally, its MWI Animal Health segment focuses on the distribution of animal health products, catering to veterinary practices and agricultural businesses.
Global Reach and Strategic Expansion
While Cencora is a dominant player in the U.S. pharmaceutical wholesale market, alongside competitors McKesson and Cardinal Health, it has significantly expanded its international footprint. In 2021, the acquisition of Alliance Healthcare, a leading drug wholesaler in Europe, marked a strategic move to strengthen its global presence. This expansion positions Cencora as a key player in both domestic and international markets, enabling it to leverage economies of scale and enhance its service offerings.
Value Proposition
Cencora’s value proposition lies in its ability to streamline the healthcare supply chain, ensuring that medications and healthcare products are delivered securely, consistently, and cost-effectively. By improving product access for pharmacies, providers, and patients, the company plays a critical role in enhancing healthcare delivery. Additionally, its tailored solutions for manufacturers and providers drive operational efficiency, cost control, and patient safety, further solidifying its importance in the industry.
Competitive Positioning
As one of the “Big Three” pharmaceutical wholesalers in the U.S., Cencora holds a significant market share, alongside McKesson and Cardinal Health. Together, these three companies account for over 90% of the U.S. pharmaceutical wholesale market. Cencora differentiates itself through its specialized services, such as global logistics via World Courier and its focus on animal health through MWI Animal Health. Its strategic acquisitions and commitment to innovation further bolster its competitive edge.
Industry Significance
The pharmaceutical wholesale industry is a critical component of the healthcare system, ensuring the timely and efficient distribution of life-saving medications. Cencora’s role in this ecosystem extends beyond distribution; its comprehensive service offerings address the complexities of pharmaceutical commercialization, logistics, and supply chain management. By bridging the gap between manufacturers and end-users, Cencora contributes to improved healthcare outcomes worldwide.
Conclusion
Cencora Inc. exemplifies the integration of expertise, innovation, and operational excellence in the healthcare supply chain. Its diverse business segments, strategic global expansion, and focus on enhancing healthcare delivery position it as a trusted partner for stakeholders across the healthcare spectrum. As the healthcare landscape continues to evolve, Cencora’s role in shaping efficient and effective delivery systems remains indispensable.
Cencora (NYSE: COR) has announced an agreement to repurchase approximately $50 million worth of its common stock from Walgreens Boots Alliance Holdings The repurchase will coincide with Walgreens Boots Alliance's sale of Cencora shares under Rule 144 of the Securities Act of 1933.
The share repurchase will be executed at a price equal to the Rule 144 sale price, with repurchased shares being held in treasury. This transaction occurs alongside the early settlement of previously disclosed variable prepaid forward sale contracts between Walgreens Boots Alliance and financial institutions.
Walgreens Boots Alliance's remaining Cencora shares continue to be pledged as security for other existing variable prepaid forward sale contracts. Cencora, ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, generates over $290 billion in annual revenue and employs 46,000+ team members globally.
Walgreens Boots Alliance (WBA) has announced the early settlement of certain prepaid variable share forward transactions related to Cencora shares, resulting in approximately $300 million in proceeds. The transaction involves the delivery of 6.1 million Cencora shares and a concurrent sale of 1.3 million additional shares.
Following the settlement, WBA retains approximately 12.6 million Cencora shares pledged under remaining forward contracts, scheduled to mature during March, June, and September 2025. The company's ownership in Cencora has decreased from 10% to approximately 6%. The proceeds will primarily be used for debt paydown, specifically addressing fiscal year 2026 debt maturities, and general corporate purposes.
The transaction includes a net aggregate cash payment of approximately $20 million to financial institutions. Despite the reduced ownership, WBA maintains its strategic partnership with Cencora, with Ornella Barra continuing to serve on Cencora's Board of Directors.
Cencora (NYSE: COR) reported strong financial results for its fiscal 2025 first quarter ended December 31, 2024. The company achieved revenue of $81.5 billion, marking a significant 12.8% increase compared to the same period last year.
The company's GAAP diluted earnings per share (EPS) was $2.50, compared to $2.98 in the prior year's first quarter. However, adjusted diluted EPS, excluding certain items, showed robust growth of 13.7%, reaching $3.73 compared to $3.28 in the previous year.
Following these results, Cencora has raised its adjusted diluted EPS guidance range for fiscal 2025 to $15.25 to $15.55.
Harrow (HROW) has announced a strategic partnership with Cencora (COR) to launch the 'Harrow Cares' program, aimed at improving accessibility and affordability of IHEEZO® and TRIESENCE® for retina specialists and their patients. The program offers comprehensive support services through a state-of-the-art patient support hub.
The initiative includes multiple key features: streamlined enrollment through various channels, real-time benefit verifications for rapid treatment access, flexible affordability options including commercial copay assistance with patients paying as little as $0, and ongoing support services including patient welcome calls and prior authorization denial assistance.
This partnership represents Harrow's strategic focus on expanding its presence in the U.S. retina market and demonstrates the company's commitment to improving healthcare accessibility while driving better patient outcomes.
Cencora (NYSE: COR) has scheduled its First Quarter Fiscal 2025 earnings release for Wednesday, February 5, 2025, before the NYSE opening bell. The company will host a conference call at 8:30 a.m. ET the same day, featuring President & CEO Robert P. Mauch and CFO James F. Cleary.
The earnings call will be accessible via webcast on investor.cencora.com and by telephone. U.S. and Canada participants can dial (833) 470-1428, while international callers should use +1 (404) 975-4839, with access code 427679. Replays will be available on the website and via telephone for 7 days using the access code 402593.
Cencora is a global pharmaceutical solutions organization ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, generating over $290 billion in annual revenue. The company employs 46,000+ team members worldwide.
Cencora (NYSE: COR) has completed its previously announced acquisition of Retina Consultants of America (RCA), acquiring approximately 85% interest in the leading management services organization of retina specialists. The remaining minority equity interest is retained by RCA physicians and management team members.
The transaction involved a cash outlay of $4.4 billion at closing, subject to post-closing price adjustments. This amount includes equity rollover, cash capitalization of RCA, transaction fees, expenses, and debt repayment.
The strategic acquisition strengthens Cencora's specialty leadership position and expands its MSO solutions, aiming to create differentiated value for stakeholders, including physicians and patients. Following the acquisition, Cencora has raised its Adjusted Diluted EPS guidance range to $15.15 to $15.45 for Fiscal 2025.
Cencora (NYSE: COR) has successfully closed a public offering of senior notes totaling $1.8 billion. The offering consists of three tranches: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035.
The proceeds will be used to finance the acquisition of the majority stake in Retina Consultants of America, related fees, and general corporate purposes. The offering was managed by BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Wells Fargo Securities.
Cencora (NYSE: COR) has announced pricing for three senior notes offerings totaling $1.8 billion: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035. The offering, expected to close on December 9, 2024, will fund the acquisition of Retina Consultants of America's majority stake and general corporate purposes. The offering is managed by BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Wells Fargo Securities.
Cencora (NYSE: COR) reported Q4 fiscal 2024 revenue of $79.1 billion, up 14.7% year-over-year, with full-year revenue reaching $294.0 billion, a 12.1% increase. Q4 GAAP diluted EPS was $0.02, while adjusted diluted EPS grew 16.8% to $3.34. For fiscal 2024, GAAP diluted EPS decreased 11.7% to $7.53, while adjusted diluted EPS increased 14.8% to $13.76.
The company increased its quarterly dividend by 8% to $0.55 per share and announced the acquisition of Retina Consultants of America. U.S. Healthcare Solutions revenue grew 15.7% to $71.7 billion, while International Healthcare Solutions revenue increased 5.5% to $7.4 billion in Q4.
Cencora (NYSE: COR) has announced a definitive agreement to acquire Retina Consultants of America (RCA) from Webster Equity Partners for $4.6 billion in cash. RCA is a leading management services organization of retina specialists, with nearly 300 specialists across 23 states conducting over 2 million patient visits annually. Cencora will hold approximately 85% ownership, while RCA's affiliated practices, physicians, and management will retain a minority interest. The acquisition is expected to be $0.35 accretive to Cencora's adjusted diluted EPS in its first twelve months and includes potential contingent payments up to $500 million in fiscal years 2027 and 2028.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
What does Cencora Inc. do?
How does Cencora generate revenue?
What is Cencora's competitive position in the industry?
What industries does Cencora serve?
What are Cencora's key business segments?
How has Cencora expanded internationally?
What is Cencora's role in the healthcare supply chain?
What is World Courier, and how is it related to Cencora?
What is MWI Animal Health, and what does it do?
How does Cencora support pharmaceutical manufacturers?
